Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Brookfield Asset Management: Naver, Nvidia, and Brookfield will invest in building gigawatt-scale AI cloud infrastructure in South Korea and the United States. Naver and Nvidia will expand the GAK Sejong AI factory in Sejong City to a target of 200 megawatts, aiming for completion by 2028. Naver plans to increase the deployment scale of Nvidia AI infrastructure to 1 gigawatt.

Brookfield Asset Management: Naver, Nvidia, and Brookfield will invest in building gigawatt-scale AI cloud infrastructure in South Korea and the United States. Naver and Nvidia will expand the GAK Sejong AI factory in Sejong City to a target of 200 megawatts, aiming for completion by 2028. Naver plans to increase the deployment scale of Nvidia AI infrastructure to 1 gigawatt.

智通财经智通财经2026/07/27 15:11
Show original
Brookfield Asset Management: Naver, Nvidia, and Brookfield will invest in building gigawatt-scale AI cloud infrastructure in South Korea and the United States. Naver and Nvidia will expand the GAK Sejong AI facility in Sejong City to 200 megawatts, aiming for completion by 2028. Naver plans to scale up the deployment of Nvidia AI infrastructure to 1 gigawatt.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

On Monday, storage chip concept stocks generally rose, with SanDisk (SNDK.US) up by 6%.

智通财经2026/08/17 13:51
U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds

On August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 study of Enhertu (trastuzumab deruxtecan) as a monotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has achieved highly positive results.

智通财经2026/08/17 12:56
AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds